keyword
MENU ▼
Read by QxMD icon Read
search

Vinorelbine

keyword
https://www.readbyqxmd.com/read/29046787/relapsed-and-unresectable-inflammatory-myofibroblastic-tumor-responded-to-chemotherapy-a-case-report-and-review-of-the-literature
#1
Yasuhiro Maruyama, Toshirou Fukushima, Daisuke Gomi, Takashi Kobayashi, Nodoka Sekiguchi, Akiyuki Sakamoto, Shigeru Sasaki, Keiko Mamiya, Tomonobu Koizumi
A 63-year-old female patient who had undergone cholecystectomy for inflammatory myofibroblastic tumor (IMT) in the gallbladder was referred to our hospital. The patient's disease relapsed, involving the pancreas, and was diagnosed as inoperable IMT 13 months after the cholecystectomy. The patient failed to respond to steroid and non-steroidal anti-inflammatory drug therapy, but subsequently exhibited a good response to vinorelbine and methotrexate combination chemotherapy. Little information is currently available on the efficacy of chemotherapy for adult-onset IMT...
October 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29045265/dose-escalation-study-of-concurrent-chemoradiotherapy-with-the-use-of-involved-field-conformal-radiotherapy-and-accelerated-hyperfractionation-in-combination-with-cisplatin-and-vinorelbine-chemotherapy-for-stage-iii-non-small-cell-lung-cancer-the-final-report
#2
Naruo Yoshimura, Takuhito Tada, Yoshiya Matsumoto, Kenji Sawa, Naoki Yoshimoto, Tomohiro Suzumura, Hidenori Tanaka, Shigeki Mitsuoka, Tatsuo Kimura, Tomohiro Tamiya, Tomonori Hirashima, Tomoya Kawaguchi, Shinzoh Kudoh, Masako Hosono, Kazuto Hirata
OBJECTIVES: A phase I study to determine a recommended dose of thoracic radiotherapy using accelerated hyperfractionation for unresectable non-small cell lung cancer was conducted. MATERIALS AND METHODS: We used chemotherapy of a cisplatin doublet and 2 dose levels of radiation with accelerated hyperfractionation. The radiation dose levels were: a total dose of 60 Gy in 40 fractions at level 1, and 66 Gy in 44 fractions at level 2. Eligible patients with unresectable stage III non-small cell lung cancer received cisplatin and vinorelbine...
October 17, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29044862/efficacy-and-safety-of-vinorelbine-plus-cisplatin-chemotherapy-for-patients-with-recurrent-and-or-metastatic-salivary-gland-cancer-of-the-head-and-neck
#3
Min Hee Hong, Chang Gon Kim, Yoon Woo Koh, Eun Chang Choi, Jinna Kim, Sun Och Yoon, Hye Ryun Kim, Byoung Chul Cho
BACKGROUND: The purpose of this study was to investigate the efficacy and safety of vinorelbine plus cisplatin chemotherapy in patients with recurrent and/or metastatic salivary gland cancer of the head and neck. METHODS: In this single-arm phase II study, patients with recurrent and/or metastatic salivary gland cancer were treated with i.v. vinorelbine (25 mg/m(2) ) on days 1 and 8 plus cisplatin (80 mg/m(2) ) on day 1 every 3 weeks for 4 or 6 cycles. The primary endpoint was the objective response rate...
October 16, 2017: Head & Neck
https://www.readbyqxmd.com/read/29035832/new-insights-into-vinca-alkaloids-resistance-mechanism-and-circumvention-in-lung-cancer
#4
REVIEW
Ying Zhang, Shao-Hui Yang, Xiu-Li Guo
Nowadays, lung cancer, as a health problem in worldwide, has high mortality both in men and women. Despite advances in diagnosis and surgical techniques of lung cancer in recent decades, chemotherapy is still a fundamentally and extensively useful strategy. Vinca alkaloids are a class of important and widely used drugs in the treatment of lung cancer, targeting on the Vinca binding site at the exterior of microtubule plus ends. Either intrinsic or acquired resistance to chemotherapy of Vinca alkaloids has been a major obstacle to the treatment of lung cancer, which arose great interests in studies of understanding and overcoming resistance...
October 13, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28982882/vinorelbine-plus-gemcitabine-or-cisplatin-as-first-line-treatment-of-her2-negative-advanced-breast-cancer
#5
RANDOMIZED CONTROLLED TRIAL
Kewen He, Xinzhao Wang, Xiyun Guan, Qian Yu, Qinghua Ma, Zhaoyun Liu, Zhiyong Yu
AIM: To evaluate the efficacy and toxicity of vinorelbine and gemcitabine (NG) versus vinorelbine and cisplatin (NP) in anthracycline- and taxane-pretreated patients with HER2-negative advanced breast cancer. PATIENTS AND METHODS: Patients were randomly assigned on a 1:1 schedule to receive no more than six cycles of NG or NP. Dosing for the NG group was 25 mg/m(2) vinorelbine and 1,000 mg/m(2) gemcitabine, given on days 1 and 8 every 3 weeks; for the NP group,25 mg/m(2) vinorelbine was given on days 1 and 8, and 75 mg/m(2) cisplatin was given on day 1 every 3 weeks...
October 2017: Anticancer Research
https://www.readbyqxmd.com/read/28957036/efficacy-and-safety-of-vinorelbine-plus-cisplatin-vs-gemcitabine-plus-cisplatin-for-treatment-of-metastatic-triple-negative-breast-cancer-after-failure-with-anthracyclines-and-taxanes
#6
Junbin Wang, Rongsheng Zheng, Zishu Wang, Yan Yang, Mingxi Wang, Weiyan Zou
BACKGROUND This study aimed to compare the efficacy and safety of vinorelbine plus cisplatin (NP regimen) vs. gemcitabine plus cisplatin (GP regimen) for treatment of metastatic TNBC after failure with anthracyclines and taxanes. MATERIAL AND METHODS A total of 48 patients with metastatic TNBC that failed in anthracyclines and taxanes treatment were enrolled and randomly grouped. Patients in the NP group (n=22) were given 25 mg/m² vinorelbine on days 1 and 8 and 25 mg/m² cisplatin on days 2-4 of each 21-day cycle, while subjects in the GP group (n=26) were administered 1000 mg/m² gemcitabine on days 1 and 8 and 25 mg/m² cisplatin on days 2-4 of each 21-day cycle...
September 28, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28941151/recurrent-desmoplastic-small-round-cell-tumor-responding-to-an-mtor-inhibitor-containing-regimen
#7
Nidale Tarek, Andrea Hayes-Jordan, Laura Salvador, Mary F McAleer, Cynthia E Herzog, Winston W Huh
Desmoplastic small round cell tumor (DSRCT) is a rare mesenchymal tumor that typically presents with multiple abdominal masses. Initial treatment is multimodal in nature. Patients with relapsed DSRCT have a poor prognosis, and there are no standard therapies. We report our experience with five patients treated with vinorelbine, cyclophosphamide, and temsirolimus (VCT). Median number of VCT courses delivered was 7 (range 4-14 courses), and partial response was observed in all patients. Median time to progression or relapse was 8...
September 22, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28928841/lung-cancer-requires-multidisciplinary-treatment-to-improve-patient-survival-a-case-report
#8
Aldo Pezzuto, Fabrizio Terzo, Maria Laura Graziani, Alberto Ricci, Pierdonato Bruno, Salvatore Mariotta
The present study reports two cases of lung cancer with the involvement of the pleura. The diagnosis of adenocarcinoma with epidermal growth factor receptor (EGFR) mutation was made following repeated thoracentesis with cytology of pleural fluid and thoracoscopy with pleural biopsies. Talc pleurodesis was successfully performed in both cases subsequent to diagnosis. Following talc pleurodesis, the first patient (62 years old; male; non-smoker) underwent 3 cycles of cisplatin/vinorelbine chemotherapy, with a poor response...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28927112/non-small-cell-lung-cancer-pc-9-cells-exhibit-increased-sensitivity-to-gemcitabine-and-vinorelbine-upon-acquiring-resistance-to-egfr-tyrosine-kinase-inhibitors
#9
Junko Hamamoto, Hiroyuki Yasuda, Kaito Aizawa, Makoto Nishino, Shigenari Nukaga, Toshiyuki Hirano, Ichiro Kawada, Katsuhiko Naoki, Tomoko Betsuyaku, Kenzo Soejima
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKIs) are widely used for the treatment of non-small cell lung cancers (NSCLCs) harboring EGFR-activating mutations. However, lung cancer cells inevitably acquire resistance to these EGFR-TKIs. The majority of patients whose lung cancer acquires resistance to EGFR-TKIs are subjected to treatment using cytotoxic agents. The present study aimed to determine if lung cancer cells acquiring resistance to EGFR-TKIs also develop altered sensitivity to cytotoxic agents...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28915900/a-randomized-phase-ii-study-to-assess-the-effect-of-adjuvant-immunotherapy-using-%C3%AE-galcer-pulsed-dendritic-cells-in-the-patients-with-completely-resected-stage-ii-iiia-non-small-cell-lung-cancer-study-protocol-for-a-randomized-controlled-trial
#10
Hideo Saka, Chiyoe Kitagawa, Yukito Ichinose, Mitsuhiro Takenoyama, Hidenori Ibata, Tatsuo Kato, Koji Takami, Motohiro Yamashita, Tadashi Maeda, Sadanori Takeo, Hitoshi Ueda, Kan Okabayashi, Seiji Nagashima, Tadayuki Oka, Hidenori Kouso, Seiichi Fukuyama, Kentaro Yoshimoto, Mototsugu Shimokawa, Akiko M Saito, Suminobu Ito
BACKGROUND: As the toxicity associated with the α-GalCer-pulsed dendritic cell (DC) therapy could be considered to be negligible, its addition to postoperative adjuvant chemotherapy would be expected to greatly improve the therapeutic effect, and could result in prolonged survival. The aim of the present study is to compare the therapeutic efficacy of alpha-galactosylceramide-pulsed DC therapy in patients who have undergone a complete resection of stage II-IIIA non-small-cell lung cancer (NSCLC) followed by postoperative adjuvant therapy with cisplatin plus vinorelbine, to that in patients who did not receive additional treatment (surgical resection plus postoperative adjuvant chemotherapy only)...
September 15, 2017: Trials
https://www.readbyqxmd.com/read/28911085/a-randomized-open-label-multicenter-phase-3-study-to-compare-the-efficacy-and-safety-of-eribulin-to-treatment-of-physician-s-choice-in-patients-with-advanced-non-small-cell-lung-cancer
#11
N Katakami, E Felip, D R Spigel, J-H Kim, M Olivo, M Guo, H Nokihara, J C-H Yang, N Iannotti, M Satouchi, F Barlesi
Background: Eribulin is a microtubule dynamics inhibitor with a novel mechanism of action. This phase 3 study aimed to compare overall survival (OS) in patients with heavily pretreated non-small cell lung cancer (NSCLC) receiving eribulin to treatment of physician's choice (TPC). Patients and methods: Patients with advanced NSCLC who had received ≥2 prior therapies, including platinum-based doublet and epidermal growth factor receptor tyrosine kinase inhibitor, were randomly assigned to receive eribulin or TPC (gemcitabine, pemetrexed, vinorelbine, docetaxel)...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28878924/serpentine-supravenous-hyperpigmentation
#12
Indirakshi Jamalpur, Harikrishna Reddy Mogili, Abhilash Koratala
Serpentine supravenous hyperpigmentation is a peculiar cutaneous eruption that follows the path of vein after intravenous injection of the chemotherapeutic agent. The lesions gradually resolve spontaneously if administration of the offending agent is stopped through the affected limb. Drugs such as 5-fluorouracil, docetaxel, vinorelbine, hydroxychloroquine, fotemustine, and minocycline are implicated.
September 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/28869796/anti-tumor-effects-of-eribulin-depend-on-the-modulation-of-tumor-microenvironment-by-vascular-remodeling-in-mouse-models
#13
Ken Ito, Shusei Hamamichi, Takanori Abe, Tsuyoshi Akagi, Hiroshi Shirota, Satoshi Kawano, Makoto Asano, Osamu Asano, Akira Yokoi, Junji Matsui, Izumi O Umeda, Hirofumi Fujii
We previously reported that eribulin mesylate (eribulin), a tubulin-binding drug (TBD), could remodel tumor vasculature (i.e., increased tumor vessels and perfusion) in human breast cancer xenograft models; however, a role of this vascular remodeling in anti-tumor effects is not fully understood. Here, we investigated the effects of eribulin-induced vascular remodeling on anti-tumor activities in multiple human cancer xenograft models. Microvessel densities (MVDs) were evaluated by immunohistochemistry (CD31 staining), and anti-tumor effects were examined in 10 human cancer xenograft models...
September 4, 2017: Cancer Science
https://www.readbyqxmd.com/read/28766886/small-cell-lung-carcinoma-cell-line-screen-of-etoposide-carboplatin-plus-a-third-agent
#14
Beverly A Teicher, Thomas Silvers, Michael Selby, Rene Delosh, Julie Laudeman, Chad Ogle, Russell Reinhart, Ralph Parchment, Julia Krushkal, Dmitriy Sonkin, Larry Rubinstein, Joel Morris, David Evans
The SCLC combination screen examined a 9-point concentration response of 180 third agents, alone and in combination with etoposide/carboplatin. The predominant effect of adding a third agent to etoposide/carboplatin was additivity. Less than additive effects occurred frequently in SCLC lines sensitive to etoposide/carboplatin. In SCLC lines with little or no response to etoposide/carboplatin, greater than additive SCLC killing occurred over the entire spectrum of SCLC lines but never occurred in all SCLC lines...
August 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28761967/survival-data-for-postoperative-adjuvant-chemotherapy-comprising-cisplatin-plus-vinorelbine-after-complete-resection-of-non-small-cell-lung-cancer
#15
Hirotsugu Kenmotsu, Yasuhisa Ohde, Kazushige Wakuda, Kazuhisa Nakashima, Shota Omori, Akira Ono, Tateaki Naito, Haruyasu Murakami, Hideaki Kojima, Shoji Takahashi, Mitsuhiro Isaka, Masahiro Endo, Toshiaki Takahashi
PURPOSE: Despite the efficacy of postoperative adjuvant cisplatin (CDDP)-based chemotherapy for patients who have undergone surgical resection of non-small cell lung cancer (NSCLC), few reports have presented survival data for Asian patients treated with adjuvant chemotherapy involving a combination of CDDP and vinorelbine (VNR). This study was performed to evaluate the survival of patients with NSCLC who received postoperative adjuvant chemotherapy comprising CDDP + VNR. METHODS: We retrospectively evaluated patients with NSCLC who received adjuvant chemotherapy comprising CDDP + VNR at the Shizuoka Cancer Center between February 2006 and October 2011...
July 31, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28738258/open-label-multicentre-randomised-phase-ii-study-of-the-epssg-and-the-itcc-evaluating-the-addition-of-bevacizumab-to-chemotherapy-in-childhood-and-adolescent-patients-with-metastatic-soft-tissue-sarcoma-the-bernie-study
#16
RANDOMIZED CONTROLLED TRIAL
Julia C Chisholm, Johannes H M Merks, Michela Casanova, Gianni Bisogno, Daniel Orbach, Jean-Claude Gentet, Anne-Sophie Thomassin-Defachelles, Pascal Chastagner, Stephen Lowis, Milind Ronghe, Kieran McHugh, Rick R van Rijn, Magalie Hilton, Jeanette Bachir, Sabine Fürst-Recktenwald, Birgit Geoerger, Odile Oberlin
PURPOSE: We evaluated the role of bevacizumab as part of the multi-modality treatment of children and adolescents with metastatic rhabdomyosarcoma (RMS) or non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). PATIENTS AND METHODS: Eligible patients aged ≥6 months to <18 years were randomised to receive induction chemotherapy (four cycles of IVADo + five cycles of IVA, ±bevacizumab), surgery and/or radiotherapy, followed by maintenance chemotherapy (12 cycles of low-dose cyclophosphamide + vinorelbine, ±bevacizumab)...
September 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28732018/carboplatin-with-intravenous-and-subsequent-oral-administration-of-vinorelbine-in-resected-non-small-cell-lung-cancer-in-real-world-set-up
#17
MULTICENTER STUDY
Vítězslav Kolek, Ivona Grygárková, Leona Koubková, Jana Skřičková, Jiřina Švecová, Dimka Sixtová, Jiří Bartoš, Aleš Tichopád
OBJECTIVES: Adjuvant cisplatin-based chemotherapy is recommended for routine use in patients with Stage IIA, IIB or IIIA non-small cell lung cancer (NSCLC) after complete resection. Results obtained for Stage IB were not conclusive. While vinorelbine plus cisplatin is the preferred choice after resection, combining vinorelbine with carboplatin promises improved compliance and delivery of drugs due to lower toxicity. We evaluated the impact of this option on treatment compliance and survival under real-world conditions...
2017: PloS One
https://www.readbyqxmd.com/read/28717760/pilot-survey-of-breast-cancer-management-in-sub-saharan-africa
#18
Verna D N K Vanderpuye, Olufunmilayo I Olopade, Dezheng Huo
PURPOSE: To understand the current state of breast cancer management in sub-Saharan Africa. METHODS: We conducted an anonymous online survey of breast cancer management among African Organization for Research and Treatment in Cancer (AORTIC) members by using a 42-question structured questionnaire in both English and French in 2013. RESULTS: Twenty members from 19 facilities in 14 countries responded to the survey. Twelve members (60%) belonged to a multidisciplinary breast cancer team...
June 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28717337/effect-of-surface-modification-on-the-in-vitro-protein-adsorption-and-cell-cytotoxicity-of-vinorelbine-nanoparticles
#19
Nandhakumar Sathyamoorthy, Dhanaraju Dasaratha Magharla, Sundar Devendaran Vankayalu
CONTEXT: Nanocarriers possessing long-circulating abilities could take advantage of the pathophysiology of tumor vasculature to achieve spatial placement. To attain such qualities, the drug carriers should possess suitable physicochemical properties such as size and surface hydrophilicity. AIM: The aim of this study was to prepare poly(ε-caprolactone) nanoparticles (NPs) loaded with vinorelbine bitartrate (VB) and to modify its steric properties using polyethylene glycol and poloxamer...
April 2017: Journal of Pharmacy & Bioallied Sciences
https://www.readbyqxmd.com/read/28683775/alk-rearranged-lung-squamous-cell-carcinoma-responding-to-alectinib-a-case-report-and-review-of-the-literature
#20
Nobuaki Mamesaya, Kazuhisa Nakashima, Tateaki Naito, Takashi Nakajima, Masahiro Endo, Toshiaki Takahashi
BACKGROUND: Although anaplastic lymphoma kinase (ALK) fusion genes are generally identified in lung adenocarcinoma patients, they are relatively rare in patients with squamous cell carcinoma (SqCC). Metastatic ALK-rearranged lung adenocarcinoma patients treated with ALK inhibitors demonstrate higher response rates, improved progression-free survival, and reduced toxicity relative to those treated with conventional chemotherapy regimens. However, the efficacy of treatment with ALK inhibitors in patients with ALK-rearranged lung SqCC remains unknown...
July 6, 2017: BMC Cancer
keyword
keyword
31933
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"